ライフサイエンスコーパス: maximum dose

1 nd a 20-wk open-label extension (OLE) at the maximum dose.

2 ich however was applied at a 50 times higher maximum dose.

3 r soy, and most reactions occurred after the maximum dose.

4 L cholesterol level, by more than 50% at the maximum dose.

5 the toxicity profile and set limitations on maximum dosing.

6 placebo or flexibly dosed pramipexole (mean maximum dose=1.7 mg/day, SD=1.3) added to existing mood

7 eceive intravenous dexamethasone (0.5 mg/kg, maximum dose 10 mg) or saline, every 6 hrs for six doses

8 l of placebo (bid), low-dose MPH (0.3 mg/kg; maximum dose, 10 mg bid), and moderate-dose MPH (0.6 mg/

9 aily subcutaneous doses of 1 mg/kg anakinra (maximum dose, 100 mg) or saline (placebo).

10 rubicin 50 mg/m(2), vincristine 1.4 mg/m(2) (maximum dose 2 mg), and rituximab 375 mg/m(2) on day 1,

11 andomized to MTX 15 mg/m2 body surface area (maximum dose 20 mg) once a week while continuing on UDCA

12 m and droperidol as directed by radiologist, maximum doses 20 mg and 5 mg respectively).

13 0 mg bid), and moderate-dose MPH (0.6 mg/kg; maximum dose, 20 mg bid).

14 M to receive aficamten (starting dose, 5 mg; maximum dose, 20 mg) or placebo for 24 weeks, with dose

15 ioperative dose of dexamethasone (0.5 mg/kg; maximum dose, 20 mg), with an equivalent volume of 0.9%

16 citalopram was 16.5 (6.5) mg by mouth daily (maximum dose, 20 mg/d).

17 umine [0.1 mmol per kilogram of body weight, maximum dose, 20 mL]) for hepatobiliary indications were

18 ceive intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg) infused over 15 to 30 minutes (n

19 ndomized 1:1 to either placebo or metformin (maximum dose, 2500 mg) in addition to usual care.

20 and >/= 25 kg) and chewable tablet 6 mg/kg (maximum dose 300 mg) twice daily (2 to <12 years) was we

21 months of daily self-administered isoniazid (maximum dose, 300 mg; 9H-SAT).

22 ree times a day up to 1 g three times a day (maximum dose 3000 mg per day) from day 5 to day 35, and

23 inib by mouth twice a day at 2 mg/m(2)/dose (maximum dose = 4 mg twice a day) in a 3-week on/1-week o

24 Mirdametinib given at 2 mg/m(2)/dose (maximum dose, 4 mg) twice daily in a 3-week on/1-week of

25 mumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other week for

26 ptomatic myeloma were also treated as above (maximum dose 400 mg) and received dexamethasone 20 mg/m(

27 usion of IdU (200 mg/m(2) body surface area; maximum dose, 400 mg) over a 30-minute period; the IdU h

28 rsus 4.7 mg/day), a longer number of days to maximum dose (5.7 days versus 3.9 days), and a maximum r

29 continue on risperidone if they had a higher maximum dose (5.7 mg/day versus 4.7 mg/day), a longer nu

30 /kg/week), etanercept alone (0.8 mg/kg/week, maximum dose 50 mg), or etanercept plus MTX for 3 years

31 domization to degludec/liraglutide (n = 278; maximum dose, 50 U of degludec/1.8 mg of liraglutide) or

32 Intra-arterial tenecteplase (0.0625 mg/kg, maximum dose 6.25 mg) administered proximal to the resid

33 lone or matching enteral adjunctive placebo (maximum dose 63 mg/kg per day for patients weighing <=28

34 , to receive 25% albumin (2 g [8 mL] per kg; maximum dose 750 mL) or the equivalent volume of isotoni

35 zophrenia was shown in early phase 2 trials (maximum dose, 750 mg/d).

36 intravenous alteplase (0.9 mg/kg bodyweight, maximum dose 90 mg per patient) was administered as earl

37 tidepressant regimens, received either DHEA (maximum dose = 90 mg/day) or placebo for 6 weeks in a do

38 flexibly dosed treatment with oxcarbazepine (maximum dose 900-2400 mg/day) or placebo.

39 ntine (maximum dose, 900 mg) plus isoniazid (maximum dose, 900 mg) (3HP-DOT) and 31% for 9 months of

40 f directly observed once-weekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose, 900

41 ion daily dose (HDD) was defined as half the maximum dose above which no further clinical benefit has

42 atment-refractory depression (at least three maximum-dose, adequate-duration medication treatments),

43 atment-refractory depression (at least three maximum-dose, adequate-duration medication treatments),

44 The maximum dose administered was 1 x 10(11) PFU per dose.

45 red using analyses of variance with a PCD-CT maximum dose and resolution scan (96 mGy, BV89) serving

46 Future studies will investigate maximum dose and toxicity to further explore the therape

47 rsensing was observed in 20 of 21 devices at maximum doses and in 17 of 20 devices at typical doses.

48 nstraint; IPSA2, without a constraint on the maximum dose; and IPSA2-0, identical to IPSA2 but withou

49 The maximum dose at mammography assessed in 1-mm(3) voxels w

50 s of SDI at TL were age, corticosteroid use (maximum dose at T0), number of American College of Rheum

51 phics, comorbid conditions, time to reaching maximum dose, buprenorphine discontinuation, and pre-bup

52 to phenotypic or microenvironmental factors; maximum dose density chemotherapy hastens rapid expansio

53 eement with TPS-calculated results, with the maximum dose difference recorded at 2.20% for the single

54 At the maximum dose, diltiazem (maximum relaxation, 95%+/-2% [p

55 MTD was not reached (maximum dose evaluated, 200 mg twice a day); 150 mg once

56 abdomen was 15.12 cGy and 0.97 cGy while the maximum dose for the skin was 17.3 cGy and 1.32 cGy.

57 to 6 mg twice daily, up to 10 mg twice daily maximum dose) if there was no axitinib-related grade 2 o

58 gnant lesions in doses of 2 MBq/kgBW and the maximum dose image (gold standard).

59 and a phase II trial of HPV16 L2E7E6 at the maximum dose in 29 women with high-grade anogenital intr

60 tomography: IPSA1, with a constraint on the maximum dose in the target volume; IPSA1-0, identical to

61 The maximum dose-intensity achieved with the first two cycle

62 At the maximum dose investigated, complete amorphization was no

63 The maximum dose is calculated as a function of 5 variables:

64 5% of the critical structure volume (D(5%)), maximum dose, mean dose, and normal tissue complication

65 thyroid volume, minimum dose, average dose, maximum dose, number of treatments, and relative volume

66 longed reduction of WBCs was observed at the maximum dose of (90)Y-anti-CD20 IgG, whereas pretargetin

67 Cell dose was not limited by toxicity with a maximum dose of 1 x 10(11) engineered T cells administer

68 In tumor tissue, a maximum dose of 12.2 Gy per GBq of (131)I-BA52 was calcu

69 ere then treated in the phase 2 study at the maximum dose of 130 mg/m2 per day for 3 days.

70 Escalation of oxaliplatin to the maximum dose of 130 mg/m2 was well tolerated in all pati

71 A model was developed that calculates the maximum dose of 131I that may be dispensed to an outpati

72 g, which could be increased, as needed, to a maximum dose of 150 mg daily, for a total of 12 weeks.

73 ramate doses were titrated over 6 weeks to a maximum dose of 150 mg twice daily.

74 xicity, a dose escalation of paclitaxel to a maximum dose of 170 mg/m(2)/d was prescribed.

75 2; and vincristine (1.5 mg/m(2) per day to a maximum dose of 2 mg, or 0.05 mg/kg per day for children

76 or 2 x 10(6) cells per kg body weight, to a maximum dose of 2 x 10(8) cells per infusion (cohort B).

77 resh DIAVIS T cells were administered with a maximum dose of 2 x 104 CD3+ cells/kg body weight.

78 eceived riociguat individually adjusted to a maximum dose of 2.5 mg three times a day.

79 eceived riociguat individually adjusted to a maximum dose of 2.5 mg three times per day.

80 in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching p

81 depending on weight, and then titrated to a maximum dose of 20 or 30 mg/d over 4 weeks.

82 t an initial dose of 50 mg/d (escalated to a maximum dose of 200 mg/d based on tolerability and respo

83 The maximum dose of 20kJ/m(2) produced 3.5-4mug vitamin D3/c

84 eceive intravenous tenecteplase (0.25 mg/kg, maximum dose of 25 mg) or intravenous alteplase (0.9 mg/

85 r day, up-titrated until intolerance or to a maximum dose of 25 mg/kg or 50 mg/kg per day (dependent

86 omipramine administered for 12 weeks, with a maximum dose of 250 mg/day.

87 etide in a single dose of 2.6 mg/kg, up to a maximum dose of 270 mg, based upon estimated or actual w

88 etide in a single dose of 2.6 mg/kg, up to a maximum dose of 270 mg, on the basis of estimated or act

89 1 ratio to receive gabapentin (titrated to a maximum dose of 2700 mg daily) or matching placebo for 1

90 Azathioprine, up to a maximum dose of 3 mg/kg/d, was prescribed for all partic

91 tching placebo dose adjusted from 50 mg to a maximum dose of 300 mg.

92 (2)/d with intrapatient dose escalation to a maximum dose of 300 mg/m(2)/d.

93 ion, odronextamab was administered up to the maximum dose of 320 mg once per week and no dose-limitin

94 y was performed using three-min stages and a maximum dose of 40 microg/kg per min.

95 2, venetoclax orally daily with ramp-up to a maximum dose of 400 mg on days 8-28, and ponatinib 45 mg

96 was started at 200 mg/d, and escalated to a maximum dose of 400 mg/d.

97 reated patients), administered at an average maximum dose of 49 mg/day.

98 ightmare response over 6 weeks to a possible maximum dose of 5 mg midmorning and 20 mg at bedtime for

99 titrated as tolerated during 4 sessions to a maximum dose of 5 mg/d, using a standardized protocol.

100 with increases every 4 weeks if needed to a maximum dose of 50 mg per day, or placebo; randomization

101 doses given on the first day, including the maximum dose of 500 mg peanut flour (cumulative dose, 99

102 2)/d, with intrapatient dose escalation to a maximum dose of 500 mg/m(2)/d.

103 ting dose was 2 microg/kg/d and increased to maximum dose of 6 microg/kg/d (average dose, 0.33 mg/d).

104 MAS-ER doses were titrated over 2 weeks to a maximum dose of 60 mg daily, and topiramate doses were t

105 A dose escalation to a maximum dose of 60 mg/m2/d was prescribed.

106 ose of 150 mg per day that was adjusted to a maximum dose of 600 mg per day or matching placebo for u

107 peak fractional dose of 2.72 Gy and a total maximum dose of 65 Gy.

108 netoclax was dose-escalated from 200 mg to a maximum dose of 800 mg daily for up to 2 years.

109 as increased by 200 mg every 2 weeks until a maximum dose of 800 mg or prohibitive toxicity was reach

110 A maximum dose of 800 mg, 600 mg, 400 mg, and 200 mg was r

111 1-3, and carboplatin area under the curve 5 [maximum dose of 800 mg] on day 2), or R-GDP (rituximab 3

112 upper GI tract, which was dose-limiting at a maximum dose of 875 mg/m(2) (doxorubicin equivalent, 25

113 25 mg) or intravenous alteplase (0.9 mg/kg, maximum dose of 90 mg).

114 The mean (SD) maximum dose of citalopram was 16.5 (6.5) mg by mouth da

115 iology and Chronic Health Evaluation II, and maximum dose of norepinephrine day 1) (hazard ratio, 2.9

116 The FABF response to the maximum dose of norepinephrine was also attenuated durin

117 h symptoms that were not controlled with the maximum dose of opioid were treated with adjunctive phen

118 The maximum dose of sertraline was 50 mg/day.

119 mol/L (>70 mg/dL) who are already taking the maximum dose of statins or are intolerant to statins, sh

120 hours), inotrope score (calculated from the maximum dose of the individual inotropic agents administ

121 The maximum dose of topotecan plus M6620 is tolerable.

122 We found that the maximum dose of UV radiation in the B range (UVB; 280-32

123 5.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy.

124 Maximum doses of either carbachol or isoprenaline had no

125 gous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction f

126 When residual inflammation remains after maximum doses of single agents, as is usually the case,

127 ad been adjusted before randomization to the maximum dose on the manufacturer's label that did not ca

128 ad been adjusted before randomization to the maximum dose on the manufacturer's label that did not ca

129 with hypertension (using >/=2 medications at maximum doses or >2 at moderate doses) and a body mass i

130 rtension receiving at least 2 medications at maximum doses or more than 2 medications at moderate dos

131 ied by dose of pirfenidone (2403 mg/day [the maximum dose] or <2403 mg/day).

132 7 months after initiation of treatment with maximum-dose pazopanib and less than 1 month after compl

133 ed with MC model for output factor, depth of maximum dose, PDDs, dose profiles, and TPR(20/10.) The e

134 The maximum number of treatments and maximum dose per treatment are set by fungicide manufact

135 The maximum dose rate, which is limited by the power density

136 The maximum dose received for the abdomen was 15.12 cGy and

137 Our data support the revision of the current maximum dose restriction of metformin in the target popu

138 tely 60%, even in patients already receiving maximum-dose statin therapy.

139 ed tolerability in cynomolgus monkeys at the maximum dose tested of 3 mg/kg.

140 The maximum dose that could be administered daily was limite

141 followed by an extension phase involving the maximum dose that could be administered without adverse

142 increasing the dose of dBG to 300 mg/m2 (the maximum dose that could be delivered i.p. in a standard

143 At the maximum doses that were associated with an acceptable le

144 The near-maximum dose to the macula showed the strongest correlat

145 The near-maximum dose to the retina was the only variable with cl

146 Maximum dose to the vessel wall was 30 to 55 Gy.

147 gs challenge the existing flawed paradigm of maximum dose treatment, a strategy that inevitably produ

148 Maximum dose was 28 mg per day, titrated against bodywei

149 The median CE maximum dose was 66 Gy (range, 44-71 Gy); the median vol

150 counting for measured covariates, cumulative maximum dose was associated with increased risk of ASD (

151 predefined stabilization criteria after the maximum dose were classified as treatment failure, at wh

152 th charged particles can potentially deliver maximum doses while minimizing irradiation of surroundin

153 The MTD was defined as the maximum dose with </= 20% risk of severe toxicity.

154 mg of liraglutide) or glargine (n = 279; no maximum dose), with twice-weekly titration to a glucose

155 1:1 to receive xanomeline-trospium chloride (maximum dose xanomeline 125 mg/trospium 30 mg) or placeb